Pharma Update
Lunsumio and Columvi: Tailored to address diverse patient and
healthcare system needs in off-the-shelf approach
Lunsumio
•
Approved in 3L+ follicular lymphoma
High CR rate and durable responses
Favorable tolerability with low grade CRS
• No required hospitalization
For outpatient setting, indolent disease (FL) and
elderly/unfit patients
Roche
COLUMVI
glofitamab
Lunsumi
CD20 x CD3 development program moving into earlier lines
Lunsumio+lenalidomide
Lunsumio
Indication
3L+ FL
Phi Phil Ph III
US/EU approved
Readout 2024
Regimen
Lunsumio
Lunsumio +Polivy
2L+ DLBCL (SCT-ineligible) SUNMO
2L+ FL
CELESTIMO
r/r CLL
1L DLBCL (elderly/unfit)
Lunsumio + Polivy
1L DLBCL (elderly/unfit)
Indication
Phl Ph II
Ph III
3L+ DLBCL
US/EU approved
Readout 2024
Lunsumio
Columvi
Approved in 3L+ diffuse large B cell lymphoma
• Best in class efficacy potential, high CR rates and
durable responses comparable to CAR-Ts
• Well tolerated with low grade, predictable CRS; low
rate of ICANS and discontinuations
Regimen
Columvi
Columvi GemOx
Columvi +CD19x4-1BBL
Columvi +CD19xCD28
Columvi + Polivy + R-CHP
• Minimal CRS in 1L DLBCL combined with R + chemo
For aggressive disease (1L DLBCL, R/R DLBCL, MCL)
.
2L+ DLBCL (SCT-ineligible) STARGLO
r/r NHL
r/r NHL
1L DLBCL
Ph III to initiate in 2023
Ph III readouts for Columvi + GemOx in 2L+ DLBCL (STARGLO) and Lunsumio + Polivy in
2L + DLBCL (SUNMO) expected 2024
CR=complete response; CRS-Cytokine Release Syndrome; r/r-relapsed refractory; FL-follicular lymphoma; DLBCL-diffuse large B-cell lymphoma; CLL=chronic lymphocytic leukemia; SCT=stem cell transplantation;
NHL-non-Hodgkin's lymphoma; GemOx-gemcitabine oxaliplatin; R-CHP-rituxan + cyclophosphamide + hydroxydaunorubicin + prednisone; ICANS=Immune Effector Cell-associated Neurotoxicity Syndrome; R=Rituximab;
MCL Mantle Cell Lymphoma
89View entire presentation